GU Cancers 2020 | Biomarkers in RCC
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Martin Voss, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the main clinically useful biomarkers in renal cell carcinoma (RCC), how they can be used in decision-making, and whether why are ready from prime time. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up